eBook: Cell and Gene Therapy - 29

CAR-T Target Luciferase Reporter Cell Lines
One of the bottlenecks in CAR-T therapeutic development is evaluating the biofunction of effector cells. This in vitro process involves a
series of labor-intensive co-culture immunoassays. To address this challenge ATCC generated CAR-T Target Luciferase Reporter Cells lines
that have high endogenous expression of clinically relevant cell surface tumor antigens, such as CD19, CD20, and HER2.
These new immuno-oncology tools are comprised of both solid and liquid tumor cell lines that exhibit sensitive and stable luciferase
reporter expression enabling your immuno-therapeutic breakthroughs by allowing you to monitor the potency and efficacy of candidate
CAR-T effector cells in your cytotoxicity and cell viability assays in real time.
These target cells can also be incorporated in other immuno-oncology applications such as Antibody Dependent Cellular Cytotoxicity
(ADCC) and natural killer (NK) cell cytotoxicity assays.
 High expression stability of both target antigen and luciferase
 High-performing, fully authenticated cell lines
 High signal-to-noise ratio (S/N)
 Easy-to-use reporter system
 Physiologically relevant low E:T ratios
 Real-time, live-cell imaging possible
For more information visit www.atcc.org/CAR-T_Target
Credible leads to Incredible®
©2023 American Type Culture Collection. The ATCC trademark and trade name, and any other trademarks listed in this publication are trademarks owned by the American Type Culture
Collection unless indicated otherwise.
http://www.atcc.org/CAR-T_Target
eBook: Cell and Gene Therapy

Table of Contents for the Digital Edition of eBook: Cell and Gene Therapy
